Amid the challenges of a global pandemic, parts of the medtech sector were positioned to reap some of the spoils enjoyed by the big pharma players. As the pandemic recedes, the demand for these assays – which were often available free of charge to the general public – has inevitably crashed.
At the midpoint of 2022, the state of the medtech market has little to recommend it, with share prices falling and a stagnant deal-making situation. But the medium-term future remains strong, if not spectacular.
Download our infographic for key insights based on Evaluate Medtech consensus forecasts to 2028.
